Anna Porwit
1 – 10 of 56
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group
(
- Contribution to journal › Article
-
Mark
Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high dose chemotherapy independent of MIPI and complement established high-risk factors
(
- Contribution to journal › Article
- 2022
-
Mark
A series of case studies illustrating the role of flow cytometry in the diagnostic work-up of myelodysplastic syndromes
2022) In Cytometry Part B - Clinical Cytometry(
- Contribution to journal › Article
-
Mark
Unsupervised cluster analysis and subset characterization of abnormal erythropoiesis using the bioinformatic Flow-Self Organizing Maps algorithm
(
- Contribution to journal › Article
-
Mark
EAHP 2020 workshop proceedings, pediatric myeloid neoplasms
(
- Contribution to journal › Scientific review
-
Mark
Mixed Phenotype/Lineage Leukemia : Has Anything Changed for 2021 on Diagnosis, Classification, and Treatment?
(
- Contribution to journal › Scientific review
-
Mark
The International Consensus Classification of acute myeloid leukemia
2022) In Virchows Archiv(
- Contribution to journal › Scientific review
-
Mark
Multiparameter flow cytometry in the evaluation of myelodysplasia : Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group
2022) In Cytometry Part B - Clinical Cytometry(
- Contribution to journal › Scientific review
- 2021
-
Mark
Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome
(
- Contribution to journal › Article
-
Mark
Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors
(
- Contribution to journal › Article